Urovant Sciences, Inc

46 articles with Urovant Sciences, Inc

• Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

  10/21/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced that it will be initiating part 2 of the COURAGE study, an international phase 3 trial to evaluate the safety and efficacy of vibegron for the treatment of symptoms of overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH).

• Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

  9/24/2019

  Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period

• Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance

  9/6/2019

  Urovant Sciences (Nasdaq: UROV) today announced that its parent company, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a non-binding memorandum of understanding for the creation of a significant multi-national Sumitomo Dainippon-Roivant Alliance (“Alliance”) that will include Roivant’s ownership interests in Urovant Sciences and four additional biopharmaceutical “Vant” companies.

• Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results

  8/13/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal quarter ended June 30, 2019.

• Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results

  8/6/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 first fiscal quarter financial results after the close of U.S. financial markets on Tuesday, August 13, 2019.

• Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

  6/13/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019.

• Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

  6/6/2019

  Will report financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019 after the close of U.S. financial markets on Thursday, June 13, 2019.

• Urovant Sciences to Present at Annual Roivant Pipeline Day

  6/3/2019

  Urovant Sciences announced Chief Executive Officer Keith A. Katkin will present at the annual Roivant Pipeline Day on June 6, 2019 at 1:50 p.m. ET.

• Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference

  5/30/2019

  Urovant Sciences, announced Chief Executive Officer Keith A. Katkin is scheduled to present a corporate overview at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 11:30 a.m. ET.

• 

  Clinical Catch-up from Last Week: May 5-10

  5/13/2019

  Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.

• Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting

  5/6/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced Dr. David Staskin presented positive, Phase 3 pivotal data demonstrating safety and efficacy of vibegron during a plenary session at the 2019 American Urological Association Annual Meeting (AUA) in Chicago yesterday afternoon.

• 

  6 Companies Report Positive Data in Phase III Clinical Trials

  5/6/2019

  Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.

• Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting

  4/29/2019

  Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation

• Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

  3/27/2019

  Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptoms of overactive bladder (OAB) in men who are receiving pharmacological treatment for benign prostatic hyperplasia (BPH).

• Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

  3/19/2019

  Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo

• Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder

  3/19/2019

  Vibegron met both co-primary endpoints and all seven key secondary endpoints

• 

  Vivek Ramaswamy's Urovant Headed to FDA With Vibegron After Positive Phase III Data

  3/19/2019

  The company announced positive topline results from its Phase III EMPOWUR trial of viregron in patients with overactive bladder.

• Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder

  3/18/2019

  Urovant Sciences announced it will host a conference call and live webcast to discuss topline results from the EMPOWUR international pivotal phase 3 study on Tuesday, March 19, 2019 at 8:30 a.m. ET.

• Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital

  2/22/2019

  Urovant Sciences announced it has entered into a debt financing agreement with Hercules Capital, Inc. for up to $100 million.

• Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018

  2/13/2019

  Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended December 31, 2018.